Top 10 at 10: Which ASX stocks are flying and floundering on Friday?

Stockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data.

It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms.

The market opens at 10am (eastern time) and the data is taken at 10:15am, once every ASX stock has started trading.

WINNERS

Stocks highlighted in yellow have made market-moving announcements (click headings to sort).

Code	Company	Price	%	Volume	Market Cap
AQX	Alice Queen Ltd	0.0015	50%	1,029,179	$2,530,288
CAV	Carnavale Resources	0.003	50%	916,666	$5,467,103
RBX	Resource B	0.165	27%	1,610,124	$7,419,078
MTL	Mantle Minerals Ltd	0.0025	25%	4,309,587	$10,691,210
ROG	Red Sky Energy.	0.005	25%	515,664	$21,208,909
MCT	Metalicity Limited	0.003	20%	2,698,457	$8,730,098
AHN	Athena Resources	0.007	17%	153,558	$6,422,805
AUH	Austchina Holdings	0.007	17%	99,110	$12,467,302
DDT	DataDot Technology	0.007	17%	1,000,000	$7,463,217
OXX	Octanex Ltd	0.007	17%	1,402	$1,553,866

Another Canadian lithium project acquisition.

Resource Base (ASX:RBX) has the option to acquire the Wali and Ernst Lake projects, a proverbial stone’s throw from Winsome Resources (ASX:WR1) and Patriot Battery Metals (ASX:PMT) in the James Bay district of Quebec.

LOSERS

Stocks highlighted in yellow have made market-moving announcements (click headings to sort).

Code	Company	Price	%	Volume	Market Cap
MEB	Medibio Limited	0.001	-33%	3,873,367	$6,225,891
CGS	Cogstate Ltd	1.205	-26%	694,065	$281,872,497
M24	Mamba Exploration	0.13	-26%	344,885	$10,672,084
CCE	Carnegie Cln Energy	0.0015	-25%	649,983	$31,285,147
PUA	Peak Minerals Ltd	0.004	-20%	30,000	$5,206,883
8IH	8I Holdings Ltd	0.03	-14%	9,000	$12,507,460
LCL	Los Cerros Limited	0.031	-14%	1,231,846	$25,940,144
FCL	Fineos Corp Hold PLC	1.7	-14%	314,974	$631,199,180
RIE	Riedel Resources Ltd	0.007	-13%	400,000	$10,973,656
MDR	Medadvisor Limited	0.22	-12%	24,964	$136,006,033

Biotech Cogstate (ASX:CGS) has released FY23 guidance ahead of its half year report and it doesn’t make for good reading.

Revenue delays are expected to continue to impact earnings in 2H23, it says, with some revenue from those impacted trials now expected to be recognised in FY24.